Emmaus Life Sciences, Inc announced today it has received confirmation from the Swiss Agency for Therapeutic Products (Swissmedic) of Emmaus’ application for Marketing Authorization (MA) for Endari® in Switzerland.
Read More
Emmaus Life Sciences announced today that its application for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi Arabia has been accepted by the Saudi Food and Drug Authority (SFDA).
Read More
Emmaus Life Sciences, Inc. announced today its financial results for the year ended December 31, 2020 as reported in its Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”).
Read More
Emmaus announced today that its Audit Committee will meet the week of April 19 to review and approve the filing of the company’s 2020 Annual Report on Form 10-K and related earnings release.
Read More
Emmaus Life Sciences, Inc., announced today that it has entered into an agreement with Kainos Medicine, Inc. (“Kainos”) to lead the preclinical development of Kainos’ patented IRAK4 inhibitor (KM10544) as an anti-cancer drug and further advance the research and development activity currently underway at Kainos.
Read More